文献速递血栓与止血

PUPs B-LONG 最终结果:rFIXFc 在初治血友病 B 患儿中的安全性与疗效

Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.
PubMed 文献 · Blood Adv · 2021-01-01

PUPs B-LONG 是一项开放标签 3 期研究,评估重组凝血因子 IX Fc 融合蛋白(rFIXFc)在 33 例初治(PUPs)血友病 B 男性患儿(<18 岁,内源性 FIX≤2 IU/dL)中的安全性与疗效。主要终点为抑制物发生,1 例(3.03%;95%CI 0.08%–15.76%)在 11 个暴露日(ED)后出现低滴度抑制物,无高滴度抑制物。rFIXFc 耐受良好,作为预防和治疗出血均有效。

要点

  • 33 例接受≥1 剂 rFIXFc 的患儿中,1 例(3.03%)出现低滴度抑制物,无高滴度抑制物。
  • 28 例(85%)接受预防治疗,中位给药间隔 7 天,平均每周剂量 58 IU/kg。
  • 预防治疗患者中位年化出血率(ABR)为 1.24(四分位距 0.00–2.49)。

核心结论

  • rFIXFc 在儿童初治血友病 B 患者中耐受良好,不良反应谱与儿童血友病群体预期一致。
  • rFIXFc 作为预防治疗及出血事件治疗均有效。

研究设计与样本

  • 开放标签、3 期研究,纳入男性初治(PUPs)血友病 B 患儿(年龄<18 岁,内源性 FIX≤2 IU/dL)。
  • 33 例患者接受≥1 剂 rFIXFc;26 例(79%)入组时年龄<1 岁,6 例(18%)有抑制物家族史。
  • 主要终点为抑制物发生,次要终点为年化出血率(ABR)。

主要发现

  • 28 例(85%)接受预防治疗,中位给药间隔 7 天,平均每周剂量 58 IU/kg。
  • 1 例(3.03%;95%CI 0.08%–15.76%)在 11 个 ED 后出现低滴度抑制物,未检测到高滴度抑制物。
  • 23 例(70%)发生 58 起治疗中出现的不良事件(SAE),其中 2 起评估为相关(同一患者发生 FIX 抑制和超敏反应,导致退出)。
  • 预防治疗患者中位 ABR 为 1.24(四分位距 0.00–2.49);大多数(>85%)出血事件仅需 1 次输注即可缓解。

临床怎么用

  • 对于儿童初治血友病 B 患者,rFIXFc 可作为预防治疗及出血事件治疗的选项。
  • 预防治疗中位给药间隔 7 天、平均每周剂量 58 IU/kg 的方案在本研究中显示有效。
  • 治疗期间需监测抑制物发生,尤其关注低滴度抑制物及超敏反应。

局限性

  • 本研究为开放标签、单臂设计,样本量较小(33 例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PUPs B-LONG evaluated the safety and efficacy of recombinant factor IX Fc fusion protein (rFIXFc) in previously untreated patients (PUPs) with hemophilia B. In this open-label, phase 3 study, male PUPs (age <18 years) with hemophilia B (≤2 IU/dL of endogenous factor IX [FIX]) were to receive treatment with rFIXFc. Primary end point was occurrence of inhibitor development, with a secondary end point of annualized bleed rate (ABR). Of 33 patients who received ≥1 dose of rFIXFc, 26 (79%) were age <1 year at study entry and 6 (18%) had a family history of inhibitors. Twenty-eight patients (85%) received prophylaxis; median dosing interval was 7 days, with an average weekly dose of 58 IU/kg. Twenty-seven patients (82%) completed the study. Twenty-one (64%), 26 (79%), and 28 patients (85%) had ≥50, ≥20, and ≥10 exposure days (EDs) to rFIXFc, respectively. One patient (3.03%; 95% confidence interval, 0.08% to 15.76%) developed a low-titer inhibitor after 11 EDs; no high-titer inhibitors were detected. Twenty-three patients (70%) had 58 treatment-emergent serious adverse events; 2 were assessed as related (FIX inhibition and hypersensitivity in 1 patient, resulting in withdrawal). Median ABR was 1.24 (interquartile range, 0.00-2.49) for patients receiving prophylaxis. Most (>85%) bleeding episodes required only 1 infusion for bleed resolution. In this first study reporting results with rFIXFc in pediatric PUPs with hemophilia B, rFIXFc was well tolerated, with the adverse event profile as expected in a pediatric hemophilia population. rFIXFc was effective, both as prophylaxis and in the treatment of bleeding episodes. This trial was registered at www.clinicaltrials.gov as #NCT02234310.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nolan B, Klukowska A, Shapiro A, et al. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Adv. 2021. PMID: 34242387. doi:10.1182/bloodadvances.2020004085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。